Armata Pharmaceuticals Inc (ARMP) Institutional Investor Snapshot (54 Funds, Q2 2026)

ARMP ranks #5966 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ARMP is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

54 institutions disclose a position in ARMP, but none treat it as a major bet — even Dauntless Investment Group, LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

BlackRock has added to its ARMP position for two straight quarters, increasing it by $3.2M to reach $3.6M today.

Jim Simons has trimmed its ARMP position for two straight quarters, cutting it by $117.1K while still holding $313.1K.

ARMP is up 4.7% today, and institutions have been net buyers of $10.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ARMP reported a net loss of $173.8M in its latest fiscal year.

• Not yet profitable — net loss of $173.8M in the latest fiscal year
• Revenue declined 5.2% year over year
• Net income declined year over year, from -$18.9M to -$173.8M
• Operating cash flow was negative, using $25.8M in cash
• Current ratio of 1.19x — below the conventional 1.5x liquidity buffer